LISSONI, ANDREA ALBERTO
 Distribuzione geografica
Continente #
NA - Nord America 8.524
EU - Europa 2.981
AS - Asia 939
Continente sconosciuto - Info sul continente non disponibili 11
SA - Sud America 9
AF - Africa 4
OC - Oceania 1
Totale 12.469
Nazione #
US - Stati Uniti d'America 8.359
CN - Cina 566
IT - Italia 544
SE - Svezia 491
UA - Ucraina 479
IE - Irlanda 469
DE - Germania 371
HK - Hong Kong 200
GB - Regno Unito 167
CA - Canada 165
FI - Finlandia 120
AT - Austria 108
VN - Vietnam 79
FR - Francia 65
RU - Federazione Russa 47
DK - Danimarca 43
IN - India 34
NL - Olanda 28
TR - Turchia 22
BE - Belgio 19
JP - Giappone 12
EU - Europa 9
BR - Brasile 8
IR - Iran 8
PL - Polonia 7
ES - Italia 6
KR - Corea 6
RO - Romania 5
TW - Taiwan 4
CH - Svizzera 3
RS - Serbia 3
SG - Singapore 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
AU - Australia 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
IL - Israele 1
MK - Macedonia 1
PH - Filippine 1
PK - Pakistan 1
Totale 12.469
Città #
Ann Arbor 1.843
Woodbridge 1.187
Fairfield 676
Houston 663
Jacksonville 519
Dublin 437
Chandler 414
Wilmington 399
Ashburn 349
Dearborn 335
Seattle 293
Frankfurt am Main 269
Cambridge 255
Princeton 218
New York 205
Hong Kong 189
Milan 134
Vienna 108
Altamura 106
Lawrence 104
Nanjing 104
Lachine 91
Beijing 74
Shanghai 69
Fremont 49
Andover 46
San Diego 43
Nanchang 37
Ottawa 35
Hebei 34
Boardman 29
Jiaxing 28
Toronto 28
Guangzhou 27
Helsinki 27
Shenyang 27
Changsha 23
Huizen 22
Tianjin 21
Falls Church 19
London 19
Brussels 18
Norwalk 18
Kunming 17
Lissone 16
Los Angeles 16
Detroit 15
Dong Ket 14
Hangzhou 14
Pune 14
Mountain View 13
Chicago 11
Rome 11
Jinan 9
University Park 9
Auburn Hills 8
Redmond 8
Edmonton 7
Florence 7
Lanzhou 7
Leawood 7
Moscow 7
Kiev 6
Palermo 6
Sacramento 6
San Mateo 6
Fuzhou 5
Hefei 5
Hounslow 5
Kraków 5
Taizhou 5
Tappahannock 5
Torre Del Greco 5
Brescia 4
Changchun 4
Chiswick 4
Dallas 4
Miami 4
Ningbo 4
Padova 4
Prescot 4
Taipei 4
Turin 4
Zanjan 4
Zhengzhou 4
Carate Brianza 3
Castelleone 3
Central 3
Cormano 3
Garbagnate Milanese 3
Groningen 3
Grottaglie 3
Henderson 3
Istanbul 3
Kocaeli 3
Loreto 3
Olgiate Comasco 3
Oristano 3
Perugia 3
Washington 3
Totale 9.953
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 454
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery 332
Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms 273
Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential 233
Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (Stumps) revealed similarities and differences with leiomyomas and leiomyosarcomas 230
Clinical outcome of patients with malignant tumors associated with mature cystic teratomas of the ovary: A retrospective multicenter Italian study 220
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production 205
From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach 188
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial 186
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 183
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 177
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study 171
Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer 169
Early and short-term complications after US-guided puncture of gynecologic lesions: evaluation after 1,000 consecutive cases 159
OC13. 02: Reproducibility of IETA terms in describing endometrial pathology 158
Pre-operative morphological and colour Doppler features of borderline ovarian tumours 158
Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors 155
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 153
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group 151
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 146
Uterine leiomyosarcoma: analysis of treatment failures and survival 146
External validation of diagnostic models to estimate the risk of malignancy in adnexal masses 145
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection 145
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 142
Prospective multicenter study on the clinical utility of CA 72.4 in post-menopausal patients with pelvic mass 142
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 138
Prospective multicenter study on CA 125 in postmenopausal pelvic masses 138
Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study 136
Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells 132
Brachytherapy for isolated vaginal recurrences from endometrial carcinoma 132
Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial 130
Synchronous early-stage endometrial and ovarian cancer 128
Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival 128
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas 127
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 127
Endometrial stromal sarcoma: analysis of treatment failures and survival 127
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies 126
Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help 125
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy 125
Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: Efficacy on pathological response 125
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma 123
Safety of transvaginal fine needle puncture of gynecologic masses: a report after 500 consecutive procedures 122
Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma 120
Antiemetic efficacy of granisetron in patients with gynecological malignancies 120
Color Doppler ultrasound in the preoperative assessment of adnexal masses 120
Ovarian cancer prediction in adnexal masses using ultrasound based logistic regression models: a temporal and external validation study by the IOTA group 118
Optimal treatment of early-stage ovarian cancer 118
Ultrasound in the follow-up of young patients with malignant ovarian tumors after conservative surgery 117
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 116
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis 115
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study 115
Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses 113
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 112
A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer 110
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 109
Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994 107
Endometriomas: Their ultrasound characteristics 105
Imaging in gynecological disease (7): clinical and ultrasound features of Brenner tumors of the ovary 103
Ultrasound characteristics of endometrial hyperplasia described using IETA terms 103
Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review 102
Effectiveness of autologous blood transfusion in patients undergoing radical hysterectomy 102
Clinically oriented three-step strategy to the assessment of adnexal pathology 102
Primary carcinoma of the fallopian tube. A retrospective analysis of 47 patients 102
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer 102
Second-look laparotomy in the management of fallopian tube carcinoma 101
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes 100
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 99
Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study 98
Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells 97
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma 96
Alpha-fetoprotein in the management of germ cell tumors of the ovary 93
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients 93
A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study 91
Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study 90
Ifosfamide in the treatment of malignant epithelial ovarian tumors 88
The prognostic relevance of histological type in uterine sarcomas: A cooperation task force (CTF) multivariate analysis of 249 cases 87
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice 86
Detection of abnormal intrauterine vascularization by color Doppler imaging: A possible additional aid for the follow up of patients with gestational trophoblastic tumors 84
Unilocular adnexal cysts with papillary projections but no other solid components: is there a diagnostic method that can reliably classify them as benign or malignant before surgery? 84
Tumor volume as risk factor for nodal diffusion in endometrial cancer 83
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas 81
ΔNp63 expression is associated with poor survival in ovarian cancer 79
Brain metastases from endometrial carcinoma 79
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel 76
Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis 74
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial 74
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 74
Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer 72
Neoplasie dell’apparato genitale femminile 71
Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer 70
Fertility-sparing surgery in uterine leiomyosarcoma 68
Comparison of methods for monitoring young women with stage I borderline ovarian tumor after conservative surgery 68
Total neuropathy scale items as early predictors of chemotherapy‐induced peripheral neurotoxicity 67
Surgical resection of solitary brain metastasis from ovarian carcinoma: an analysis of 22 cases 67
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer 66
Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial 65
Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females 65
A prospective study of the role of ultrasound in the management of adnexal masses in pregnancy 63
Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses 62
Ultrasound-guided aspiration of endometriomas: Possible applications and limitations 62
Totale 12.314
Categoria #
all - tutte 41.254
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.254


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019544 0 0 0 0 0 0 0 0 0 0 296 248
2019/20202.771 341 165 218 246 268 335 369 191 286 119 187 46
2020/20211.887 124 82 178 186 122 153 192 179 195 208 109 159
2021/20221.185 74 91 81 112 105 94 55 91 56 85 108 233
2022/20231.892 256 577 134 137 182 297 13 90 125 17 31 33
2023/20241.249 38 43 77 73 181 353 264 33 133 39 15 0
Totale 12.849